PLPL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PLPL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Plandai Biotechnology's enterprise value is $2.72 Mil. Plandai Biotechnology's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil. Therefore, Plandai Biotechnology's EV-to-Revenue for today is .
The historical rank and industry rank for Plandai Biotechnology's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Plandai Biotechnology was 775.77. The lowest was 40.64. And the median was 46.42.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-06-14), Plandai Biotechnology's stock price is $0.00036. Plandai Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00. Therefore, Plandai Biotechnology's PS Ratio for today is .
The historical data trend for Plandai Biotechnology's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plandai Biotechnology Annual Data | |||||||||||||||||||||
Trend | Mar09 | Mar10 | Mar11 | Jun12 | Jun13 | Jun14 | Jun15 | Jun16 | Jun22 | Jun23 | |||||||||||
EV-to-Revenue | Get a 7-Day Free Trial | 220.90 | 542.91 | 59.46 | - | - |
Plandai Biotechnology Semi-Annual Data | ||||||||||||||||
Mar03 | Mar04 | Mar05 | Mar06 | Mar07 | Mar08 | Mar09 | Mar10 | Mar11 | Jun12 | Jun13 | Jun14 | Jun15 | Jun16 | Jun22 | Jun23 | |
EV-to-Revenue | Get a 7-Day Free Trial | 220.90 | 542.91 | 59.46 | - | - |
For the Shell Companies subindustry, Plandai Biotechnology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Diversified Financial Services industry and Financial Services sector, Plandai Biotechnology's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Plandai Biotechnology's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Plandai Biotechnology's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 2.717 | / | 0 | |
= |
Plandai Biotechnology's current Enterprise Value is $2.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Plandai Biotechnology's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plandai Biotechnology (OTCPK:PLPL) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Plandai Biotechnology's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 0.00036 | / | 0 | |
= |
Plandai Biotechnology's share price for today is $0.00036.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Plandai Biotechnology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Callum Baylis-duffield | director | FLAT 37 ISLAND HOUSE THREE MILL LANE, LONDON ENGLAND X0 E33AF |
Timothy Matula | other: Former Director | 175 JACKSON AVE N, SUITE 102, MINNEAPOLIS MN 55343 |
Brian Johnson | director | P.O. BOX 1594, FERNDALE WA 98248-1594 |
Roger Duffield | director, officer: President, Secretary and CFO | 2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102 |
Daron Baylis Duffield | director | 2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102 |
David Rzepnicki | director | 21 HORIZON DRIVE, SARATOGA SPRINGS NY 12866 |
From GuruFocus
By ACCESSWIRE • 08-01-2023
By ACCESSWIRE ACCESSWIRE • 05-17-2023
By Marketwired Marketwired • 06-19-2018
By Marketwired Marketwired • 07-03-2018
By Marketwired Marketwired • 04-25-2018
By ACCESSWIRE ACCESSWIRE • 05-31-2023
By Marketwired Marketwired • 04-03-2018
By Marketwired Marketwired • 06-12-2018
By ACCESSWIRE ACCESSWIRE • 06-22-2022
By Marketwired Marketwired • 08-23-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.